Consumer Marketing briefs

Share this article:
Novo Nordisk launched the latest in its diabetes awareness campaign featuring Olympia Dukakis and her husband Louis Zorich. The duo star in new interactive features on the firm's education site, AskScreenKnow.com, aimed at getting at-risk adults 65 and up to get screened for diabetes

The first-ever TV ad for medical marijuana aired on a Fox affiliate in Sacramento, CA, Time Magazine reported. The ad promotes CannaCare and features testimonials by patients who said the product helped them deal with their pain—from ruptured discs, a car accident and bone disease.  

The American Cancer Society Cancer Action Network launched a print and online ad campaign urging congressional reps to fund the CDC's National Breast and Cervical Cancer Early Detection Program, which the group says is able to serve less than one in five eligible women at current funding levels. But ACS CAN pulled the ad days later after it came under fire from bloggers who said the ad's message—“We can't fight cancer if we can't see it”—was too vague and could be read as encouraging screening generally.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?